RNA‐PROTACs: Degraders of RNA‐Binding Proteins

Ghidini, Alice, Cléry, Antoine, Halloy, François, Allain, Frédéric H. T., Hall, Jonathan·2021·Angewandte Chemie International Edition
DOI 10.1002/anie.202012330

Cited by (199)

Items 101–199 of 199

  1. Targeting serine- and arginine-rich splicing factors to rectify aberrant alternative splicing
    Dianyang Li, Wenying Yu, Maode Lai · 2023 · Drug Discovery Today
  2. Systematic evolution of functional oligonucleotides for targeted protein degradation
    Huang Su, Yifan Chen, Xuyang Zhao, Ziang Lu, Tongxuan Wei, Qinguo Liu, Xiyang Liu, Qinhao Zhang, Siqi Bian, Qibing Qiu et al. · 2025 · Chem
  3. Taming transcription factors with TRAFTACs
    Christine S.C. Ng, Steven M. Banik · 2021 · Cell chemical biology
  4. Genome-wide landscape of RNA-binding protein (RBP) networks as potential molecular regulators of psychiatric co-morbidities: a computational analysis
    M. J. Nishanth, Shanker Jha · 2023 · Egyptian Journal of Medical Human Genetics
  5. Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine
    Sandra Kannampuzha, Reshma Murali, Abilash Valsala Gopalakrishnan, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Arunraj Namachivayam, Alex George, Abhijit Dey, Balachandar Vellingiri · 2023 · Medical Oncology
  6. Non-coding RNA and drug resistance in head and neck cancer
    Yulong Zhang, Yingming Peng, Bingqin Lin, Shuai Yang, Feiqiang Deng, Xuan Yang, An Li, Wanyi Xia, Chenxi Gao, Shaona Lei et al. · 2024 · Cancer Drug Resistance
  7. Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs
    Rui Yao, Tianli Luo, Ming Wang · 2023 · ChemBioChem
  8. RNA splicing factor RBFOX2 is a key factor in the progression of cancer and cardiomyopathy
    Jinze Shen, Jianqiao Shentu, Chenming Zhong, Qiankai Huang, Shiwei Duan · 2024 · Clinical and Translational Medicine
  9. Cytoplasmic regulation of the poly(A) tail length as a potential therapeutic target
    Mercedes Fernández, Raul Mendez · 2025 · RNA
  10. RNA G-quadruplex structure-based PROTACs for targeted DHX36 protein degradation and gene activity modulation in mammalian cells
    Kun Zhang, Qichang Nie, Maolin Li, Xiaona Chen, Liting Zhong, Tianle Dai, Xiaofan Guo, Haizhou Zhao, Terrence Chi‐Kong Lau, Huating Wang et al. · 2025 · Nucleic Acids Research
  11. The intricate dance of RNA-binding proteins: unveiling the mechanisms behind male infertility
    Ying Jun Gao, Yikun Zhou, Zhidan Hong, Binyu Ma, Xiaojie Wang, Linhang Nie, Ling Ma, Yuanzhen Zhang, Ming Zhang, Mei Wang · 2025 · Human Reproduction Update
  12. Dégradation induite des protéines par des molécules PROTAC et stratégies apparentées : développements à visée thérapeutique
    Michèle Reboud‐Ravaux · 2021 · Biologie Aujourd hui
  13. PROTACs coupled with oligonucleotides to tackle the undruggable
    Guangshuai Zhang, Si Yan, Yan Liu, Ziwei Du, Qin Min, Shuanglin Qin · 2025 · Bioanalysis
  14. DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1–CDK4/6 Complex Protein Degradation
    Rong Zheng, Abhay Prasad, Deeksha Satyabola, Yang Xu, Subhajit Roy, Yichen Yan, Petr Šulc, Hao Yan · 2025 · Journal of the American Chemical Society
  15. COVID-19 Therapies: Protease Inhibitions and Novel Degrader Strategies
    Michèle Reboud‐Ravaux, Chahrazade El Amri · 2022 · Frontiers in Drug Discovery
  16. The rise of targeting chimeras (TACs): next-generation medicines that preempt cellular events
    Scott A. Hollingsworth, Scott Arne Johnson, Pouyan Khakbaz, Yilin Meng, Varnavas D. Mouchlis, Olivia Pierce, Vera D. Prytkova, Erik Sebastian Vik, Dahlia R. Weiss, Veerabahu Shanmugasundaram · 2023 · Medicinal Chemistry Research
  17. PROTAC Degraders
    Alessio Ciulli, Oliver Hsia · 2022 · Wiley eBooks
  18. Design and synthesis of nucleic acid nano-environment interactome-targeting small molecule PROTACs and their anticancer activity
    Sadiya Tanga, Arkadeep Karmakar, Arpita Hota, Paramita Banerjee, Basudeb Maji · 2024 · Nanoscale
  19. Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs
    Si-Han Zhang, Na Zeng, Jin‐Zhou Xu, Chen‐Qian Liu, Mengyao Xu, Jian‐Xuan Sun, Ye An, Xing‐Yu Zhong, Lin-Tao Miao, Shaogang Wang et al. · 2024 · Biomedicine & Pharmacotherapy
  20. The role of RNA binding proteins in cancer biology: A focus on FMRP
    Yunlu Jia, Ruyin Jia, Yongxia Chen, Xuanyi Lin, Nadire Aishan, Han Li, Linbo Wang, Xiaochen Zhang, Jian Ruan · 2024 · Genes & Diseases
  21. Selective Proteolysis of Activated Transcriptional Factor by NIR‐Responsive Palindromic DNA Thalidomide Conjugate Inhibits the Canonical Smad Pathway
    Min Hou, Rui Guo, Tianyu Ren, Tao Wang, Jian‐Hui Jiang, Jianjun He · 2023 · Small
  22. Major Advances in Emerging Degrader Technologies
    Hang Luo, Li Wu, Yujian He, Chong Qin, Xinjing Tang · 2022 · Frontiers in Cell and Developmental Biology
  23. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies
    Yangping Wu, Jingliao Zhang, Xiaofan Zhu, Yingchi Zhang · 2022 · Cancer Letters
  24. Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapy
    Meiyang Xi, Fengxia Zhang, Jingjing Zhu, Hualiang Shen, Chunlei Wu, Xiaozhong Gao, Yonghua Wu, Yonghua Wu, Runpu Shen, Gang Xia · 2025 · European Journal of Medicinal Chemistry
  25. Targeting RNA binding proteins with small-molecule inhibitors: Advances, challenges, and therapeutic opportunities
    Yuning Shi, Dazhi Feng, Jieya Zhou, Lihua Liu, Xinnan Li, Zhenwei Yuan, Jianbing Wu, Hong Yao · 2025 · Acta Pharmaceutica Sinica B
  26. The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants
    Ye Wu, Xia Wu, Xiaojia Wang, Xiaoyu Wei, Yuqian Tang, Xianfeng Ouyang, Yuping Gong · 2022 · Frontiers in Pharmacology
  27. Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy
    Xu Zhang, Zhangzhi Song, Xinyu Zhang, Jianhua Zou, Guocan Yu, Xiaoyuan Shawn Chen, Sheng Wang · 2025 · Angewandte Chemie
  28. Targeted Degradation of Lin28B Using Pre-let-7-PROTACs for Hepatocellular Carcinoma Therapy
    Jianfei Xu, Xingxing Liang, Zhaopeng Yan, Yuejie Zhu, Jing Wang, Qian Wang, Zhenjun Yang, Xinjing Tang · 2026 · Journal of Medicinal Chemistry
  29. PROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery
    Mao Du, Tao Liu, Wenyu Wang, Shuai Fan, Mei Tian, Qing Du, Zhidong Wang, Xiaodong Li, Xiaoyu Liu, Qin Xia et al. · 2026 · European Journal of Medicinal Chemistry Reports
  30. Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
    Nikola Knoll, Nouri Neamati, Aykut Üren · 2026 · ACS Pharmacology & Translational Science
  31. From undruggable to degradable: Strategic expansion of targeted protein degradation in cancer therapy
    Jiyoon Sung, Yuna Seo, Jae-Young Lee · 2026 · Molecular Therapy
  32. Targeted Management: Unlocking the Crucial Role of PROTACs in Cancer Treatment
    Priyanka Gupta, Sumit Dutta, Prashant Kumar, Monika Kaushik, Sumel Ashique, Mithun Bhowmick · 2025 · Current Drug Discovery Technologies
  33. G‐Quadruplex RNA Based PROTAC Enables Targeted Degradation of RNA Binding Protein FMRP for Tumor Immunotherapy
    Ruixi Peng, Qian Huang, Li Wang, Gongxi Qiao, Xiangrong Huang, Jian‐Hui Jiang, Xia Chu · 2024 · Angewandte Chemie
  34. Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics
    Mingyao Huang, Fang Wei, Jilong Cao, Hongzhou Jiang · 2025 · Bioorganic Chemistry
  35. Fulfilling multiple roles in PROTAC design: The emerging potential of oligonucleotides
    Daniel Alencar Rodrigues, Gustavo Salgado Pires, Urbi Roy, Eric Conway, Pedro de Sena Murteira Pinheiro · 2026 · European Journal of Medicinal Chemistry
  36. Prospects and advances of PROTAC in the treatment of hematologic malignancies
    Xinyang Wang, Ming Zhang, Heng Mei · 2026 · Experimental Hematology and Oncology
  37. Multifaceted targeted protein degradation systems for different cellular compartments
    Cornelia E. Zorca, Armaan Fallahi, Sophie Luo, Mohamed A. Eldeeb · 2022 · BioEssays
  38. Long Non-Coding RNAs and RNA-Binding Proteins in Pancreatic Cancer Development and Progression
    Pit Preckwinkel, Khursheed Ul Islam Mir, Florian W. Otto, Hend Elrewany, Andrea Sinz, Stefan Hüttelmaier, Nadine Bley, Tony Gutschner · 2025 · Cancers
  39. Advancing PROTAC Characterization: Structural Insights through Adducts and Multimodal Tandem-MS Strategies
    Mohammed Khalilur Rahman, Bryan P. Marzullo, Stephen W. Holman, Mark P. Barrow, Andrew D. Ray, Peter B. O’Connor · 2024 · Journal of the American Society for Mass Spectrometry
  40. Comprehensive Profiling of Roquin Binding Preferences for RNA Stem‐Loops
    Lasse Oberstrass, Jan‐Niklas Tants, Chiara Lichtenthaeler, Sara E. Ali, Louisa Koch, David H. Mathews, Andreas Schlundt, Julia E. Weigand · 2024 · Angewandte Chemie International Edition
  41. Using circular RNAs to target toxic RNA-binding proteins in amyotrophic lateral sclerosis
    Anne Kruse Hollensen, Matilde Helbo Sørensen, Sofie Vesterbæk Thomsen, Henriette Sylvain Thomsen, Christian Kroun Damgaard · 2025 · Molecular Therapy — Methods & Clinical Development
  42. Proteolysis-Targeting Chimeras: A Kaleidoscope of Targeted Protein Degradation
    Yi Mou, Shuai Wen, Xinxing Gao, Zhengyu Jiang · 2021 · Future Medicinal Chemistry
  43. N-Degron PROTACs as a Potential Therapeutic Approach for Chronic Myeloid Leukemia
    Grace Hohman, Mohamed A. Eldeeb · 2025 · Anti-Cancer Agents in Medicinal Chemistry
  44. Deciphering the RNA recognition by Musashi-1 to design protein and RNA variants for in vitro and in vivo applications
    Anna Pérez‐Ràfols, Guillermo Pérez-Ropero, Linda Cerofolini, Luca Sperotto, Joel Roca‐Martínez, R. Anahí Higuera-Rodríguez, Pasquale Russomanno, W. Kaiser, Wim Vranken, U. Helena Danielson et al. · 2025 · Nucleic Acids Research
  45. Application of PROTAC Technology in Drug Development
    Prashant S. Kharkar, Atul L. Jadhav · 2022 · Methods and principles in medicinal chemistry
  46. MicroRNA‐Triggered Programmable DNA‐Encoded Pre‐PROTACs for Cell‐Selective and Controlled Protein Degradation
    Jiayin Zhan, Xiang Li, Zhe Feng, Zheng Liu, Zhiyuan Feng, Jun‐Jie Zhu, Jingjing Zhang · 2024 · Angewandte Chemie
  47. Transcription factor degraders
    Manni Wang, Yuhao Wei, Xiaoling Ma · 2025 · Elsevier eBooks
  48. From rare to prevalent: dawn of the RNA therapeutics era
    Jun Liang Zhou, Erica Shu · 2025 · Targetome
  49. Indirect ubiquitination independent of endogenous ubiquitination machinery for targeted protein degradation
    Takafumi Furuhata, Kazuki Yoshida, 藤田 凌嘉, Jotaro Miyamoto, Chiharu Moriyama, Tokiha Masuda-Ozawa, Hikaru Tsuchiya, Yasushi Saeki, Akimitsu Okamoto · 2026 · Communications Chemistry
  50. Transcript‐Level Modulation of O ‐GlcNAc Transferase for Aging‐Related Neurodegenerative Diseases
    Florian Malard · 2026 · ChemBioChem
  51. Bridging technical innovation and computational advances in studies of RNA–protein assemblies
    Luca Ducoli, Suhas Srinivasan, Eimon Amjadi, Paul A. Khavari · 2026 · Nature Reviews Genetics
  52. Bifunctional proximity-inducing strategies for targeted and programmable post-translational modifications
    Sadiya Tanga, Pallabi Das, Tuhin Baran Samoi, Arpita Hota, Arkadeep Karmakar, Basudeb Maji · 2026 · Advanced Drug Delivery Reviews
  53. Self-Splicing RNA Platform Encodes Twin PROTACs for Dual-E3 Ligase Recruitment and Programmable Protein Degradation
    Jiani Ding, Shumin Wang, Zijie Tang, YJ Li, Peisen Zhang, Zhiling Song, Xiliang Luo, Xiaobing Zhang · 2026 · Journal of the American Chemical Society
  54. RNA‐Binding Proteins: Function, Biological Mechanisms, and Therapeutic Opportunities
    Ling Li, Xiuli Yan, Qing Ji, Hui Zhang · 2026 · MedComm
  55. Targeting RNA‐binding proteins for cancer therapy
    Chengpiao Lu, Guoqiang Xu, Jingjing Ma · 2023 · Clinical and Translational Discovery
  56. Membrane‐Bounded Intracellular E3 Ubiquitin Ligase‐Targeting Chimeras (MembTACs) for Targeted Membrane Protein Degradation
    Mengwu Mo, Feiyu Wang, Huimin Zhang, Ying Zhang, Chaoyong James Yang, Jinbiao Shang, Zhi Zhu · 2025 · Angewandte Chemie
  57. DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation
    Rong Zheng, Abhay Prasad, Deeksha Satyabola, Yang Xu, Hao Yan · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  58. RNA-Binding Protein Degradation with PROTACs
    Dirk H. Trauner, Andrej Shemet · 2021 · Synfacts
  59. Spatial dimension and demographic dynamics of Kenyas urban subsystem.
    Rose A. Obudho · 1976
  60. Mechanisms of action of cytoplasmic microRNAs. Part 2. MicroRNA-mediated post-translational silencing
    А.Е. Абатуров, V.L. Babуch · 2022 · CHILD`S HEALTH
  61. Mechanisms of action of cytoplasmic microRNAs. Part 3. TNRC6-associated mechanism of miRNA-mediated mRNA degradation
    А.Е. Абатуров, V.L. Babуch · 2022 · CHILD`S HEALTH
  62. Mechanisms of action of cytoplasmic miRNAs. Part 4. Recruitment of the DCP1-DCP2 decapping complex. Mechanisms of final mRNA degradation
    А.Е. Абатуров, V.L. Babуch · 2022 · CHILD`S HEALTH
  63. Extending the Degradation Toolkit – mRNA Targeting as an Alternative Means to Affect Protein Levels
    Andrei Ursu, Barbara Herdy, Hendrik Osadnik · 2022 · Wiley eBooks
  64. The Future of Heterobifunctional Compounds: PROTACs and Beyond
    George M. Burslem · 2022 · Wiley eBooks
  65. New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
    Eric Valeur · 2023 · Royal Society of Chemistry eBooks
  66. RNP granules in ALS and neurodegeneration: From multifunctional membraneless organelles to therapeutic opportunities
    Tatyana A. Shelkovnikova, Guillaume M. Hautbergue · 2024 · International review of neurobiology
  67. Pre‐mRNA Splicing Modulation
    Scott J. Barraza, Matthew G. Woll · 2024 · Methods and principles in medicinal chemistry
  68. Induction de proximité et dégradation de cibles thérapeutiques par les nouveaux dégradeurs : quels concepts, quels développements, quel futur ?
    Michèle Reboud‐Ravaux · 2024 · Biologie Aujourd hui
  69. We are MedChem: The Frontiers in Medicinal Chemistry 2024
    Matthias Schiedel, Philipp Barbie, Felix Pape, Marta Pinto, Andrea Unzue Lopez, María M. Méndez, Gerhard Heßler, Daniel Merk, Matthias Gehringer, Christina Lamers · 2024 · ChemMedChem
  70. Detaillierte Analyse der Bindepräferenz von Roquin an RNA‐Stammschleifen
    Lasse Oberstrass, Jan‐Niklas Tants, Chiara Lichtenthaeler, Sara E. Ali, Louisa Koch, David H. Mathews, Andreas Schlundt, Julia E. Weigand · 2024 · Angewandte Chemie
  71. Deciphering the RNA recognition by Musashi-1 to design protein and RNA mutants for in vitro and in vivo applications
    Anna Pérez‐Ràfols, Guillermo Pérez-Ropero, Linda Cerofolini, Luca Sperotto, Joel Roca‐Martínez, R. Anahí Higuera-Rodríguez, Pasquale Russomanno, W. Kaiser, Wim Vranken, U. Helena Danielson et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  72. Hitting a Moving Target
    Emile P. Chen · 2025 · Wiley eBooks
  73. Integrating PROTAC technology with natural product research: A new frontier in target identification
    Baoyu Wei, Jinyun Dong, Yi Liang, Jiang‐Jiang Qin, Guoyin Kai · 2025 · Elsevier eBooks
  74. 3338 Oligonucleotide conjugates
    Andreia F. Jorge, Santiago Grijalvo, Anna Maria Aviñó, Carme Fàbrega, Ramón Eritja · 2025 · De Gruyter eBooks
  75. Modular RNA-based PROTACs for selective degradation of multidomain RNA-binding proteins
    Florian Malard, Léa Bouton, Giulia Chiarazzo, Corinne Burre, Brune Vialet, Samuel Amintas, Sébastien Campagne · 2025 · Research Square
  76. PROTACS- targeted protein degradation as a path to precision cancer therapeutics
    Hannah R Gatley, Paul B. Fisher, Swadesh Kumar Das · 2025 · Advances in cancer research
  77. Additional file 1 of Genome-wide landscape of RNA-binding protein (RBP) networks as potential molecular regulators of psychiatric co-morbidities: a computational analysis
    Nishanth, M. J., Shanker Jha · 2024 · Figshare
  78. Additional file 2 of Genome-wide landscape of RNA-binding protein (RBP) networks as potential molecular regulators of psychiatric co-morbidities: a computational analysis
    Nishanth, M. J., Shanker Jha · 2024 · Figshare
  79. Additional file 3 of Genome-wide landscape of RNA-binding protein (RBP) networks as potential molecular regulators of psychiatric co-morbidities: a computational analysis
    Nishanth, M. J., Shanker Jha · 2024 · Figshare
  80. Opportunities and challenges in targeted protein degradation for antiviral drug discovery
    Man Zhu, Maoze Yang, Hai‐Bing Zhou · 2026 · Elsevier eBooks
  81. Design and synthesis of trisubstituted 1,2,4-triazoles : structural exploration in the inhibition of GSK-3β for the treatment of Alzheimer’s disease
    Thiago M. Pereira · 2024 · theses.fr (ABES)
  82. RNA Modifications as Drug Targets: Unlocking the Therapeutic Potential of the Epitranscriptome
    Dhananjay Taumar, Atul Pratap Singh, Himanchal Sharma, Vatan Chaudhary · 2026 · Current Genomics
  83. RNA-binding protein hnRNPD induces epithelial-mesenchymal transition in Wilms’ tumor via facilitating MAP4K4 mRNA stability
    Gang Li, Man Liao, 鲍海滨, Haolun Xu, Jun Wang, Man Zhang, Can Li, Tian Zheng, Chunlei Yang · 2026 · Molecular Genetics and Genomics
  84. Alternative splicing rewires breast cancer and opens therapeutic avenues
    Yuhan Jin, Yiran Liang, Mahsa Maghsoudy Kasvaei, Qifeng Yang · 2026 · Cell Communication and Signaling
  85. The Hallmarks of Glioblastoma: Functional Interplay Between Long Non-Coding RNAs and RNA-Binding Proteins
    Karlijn A. van de Langerijt, Md. Golam Kibria, Genaro R. Villa, Marco Mineo · 2026 · Cells
  86. The splice of life: an isoform-centric view of disease, technology, and therapeutics
    Timothy Pan, Lina Lu, Ruli Gao · 2026 · Journal of Clinical Investigation
  87. RNA-based ATTEC: an RNA-guided autophagy-lysosome platform for targeted protein degradation
    Yunqiu Zhang, Wanting Yang, Yan Xu, 付丁强, Xiao‐kang Nie, Feng Du, Juan Dong, Fang Wang, Xin Cui, Zhuo Tang · 2026 · Bioorganic & Medicinal Chemistry
  88. Targeting IGF2BP3 in Cancer: From Molecular Structure and Biology to Early Drug Discovery
    Elisa Uliassi, María Laura Bolognesi, Katia Scotlandi, Caterina Mancarella · 2026 · International Journal of Molecular Sciences
  89. Targeted protein degradation: mechanistic diversity, therapeutic expansion, and clinical translation
    Caiyu Wang, Zhibin Guo, Yufei Liu, Qichao Gao, Qing Wang, Yi Liu, Yujiao Liu · 2026 · International Journal of Pharmaceutics
  90. PROTAC as a Potential Toolbox for the Discovery of New Targets and Drugs
    Mengjun Ma, Xiaolei Meng, Chong Qin · 2026 · Handbook of experimental pharmacology
  91. Branched DNA Nanoplatform-Based Multivalent PROTACs for Tumor Microenvironment-Responsive Degradation of Telomere-Binding Proteins in Tumor Therapy
    Hanyin Zhu, Xintong Li, Hong Wang, Huarui Liu, Dandan Li, Changping Yang, Baoquan Ding, Jianbing Liu · 2026 · Nano Letters
  92. From translation milestones to clinical breakthroughs: Decision-making hubs and translational strategies for RNA-binding proteins in the immunotherapy of haematological malignancies
    Peng Liu, Jingjing Liu · 2026 · Critical Reviews in Oncology/Hematology
  93. RNA-Binding Proteins Regulate Cardiovascular Disease Progression Through Alternative Splicing and Alternative Polyadenylation
    Zhaojunze Huang, Xianting Yang, Long Wang, Jiashun Huang, Yi Zhou, Xin Guo · 2026 · Journal of Cardiovascular Translational Research
  94. The cellular landscape of druggable RNA-binding proteins
    Gaia Di Timoteo, Benson M. George, Omar Ibrahim Abdel-Wahab, Ryan A. Flynn, Konstantinos Tzelepis · 2026 · Nature Reviews Drug Discovery
  95. Protein degraders targeting JAK/STAT3 signaling pathway are emerging therapeutic modalities for human cancers
    Xinyu Feng, Nanjing Li, Xiaorong Chen, Xinyue Cao, Jingling Dai, Shaoquan Xiong, Zhu Yuan · 2026 · Biochemical Pharmacology
  96. BindingDB Entry 50019272: Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.
    BindingDB · 2024 · UC San Diego
  97. BindingDB Entry 50020810: Small molecules modulating RNA splicing: a review of targets and future perspectives.
    BindingDB · 2024 · UC San Diego
  98. BindingDB Entry 50016515: Nucleic-Acid-Based Targeted Degradation in Drug Discovery.
    BindingDB · 2023 · UC San Diego
  99. BindingDB Entry 50023360: PROTAC technology: From drug development to probe technology for target deconvolution.
    BindingDB · 2026 · UC San Diego